Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

09-09-2021 | Brief Report

Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder

Auteurs: Majd Al-Soleiti, Kayla Balaj, Robyn P. Thom, Christopher J. McDougle, Christopher J. Keary

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 9/2022

Abstract

There is increasing interest in investigating cannabis for behavioral symptoms in individuals with autism spectrum disorder (ASD). The potential role of dysregulated cannabinoid signaling contributing to the pathophysiology of ASD is an area of active investigation. Results from retrospective and uncontrolled trials of cannabis in subjects with ASD have been published, reporting both potential benefits and adverse effects. Here, we describe the clinical course of three young adult males with ASD who developed mania or psychosis after the consistent use of cannabidiol and delta-9-tetrahydrocannabinol. Caution should be utilized with cannabis use in individuals with ASD until large-scale, replicated randomized controlled trials demonstrating efficacy, safety and tolerability have been published.

vorige artikel Heterogeneity in Autism Spectrum Disorder Case-Finding Algorithms in United States Health Administrative Database Analyses

volgende artikel Brief Report: The Experiences of Families of Children with an Autism Spectrum Disorder When Seeking Patient-and Family-Centered Care

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Association.CrossRef

Aran, A., Cassuto, H., Lubotzky, A., Wattad, N., & Hazan, E. (2019). Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—A retrospective feasibility study. Journal of Autism and Developmental Disorders, 49(3), 1284–1288.CrossRef

Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., Koren, G., & Berkovitch, M. (2019). Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Frontiers in Pharmacology, 9, 1521. https://doi.org/10.3389/fphar.2018.01521 (eCollection 2018).CrossRefPubMedPubMedCentral

Bridgeman, M. B., & Abazia, D. T. (2017). Medicinal cannabis: History, pharmacology, and implications for the acute care setting. Pharmacy and Therapeutics, 42(3), 180–188.PubMedPubMedCentral

Cross-Disorder Group of the Psychiatric Genomics Consortium. (2019). Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell, 179(7), 1469–1482.CrossRef

Devinsky, O., Cross, J. H., Laux, L., March, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., Wright, S., & Cannabidiol in Dravet Syndrome Study Group. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011–2020.CrossRef

Duvall, S. W., Lindly, O., Zuckerman, K., Msall, M. E., & Weddle, M. (2019). Ethical implications for providers regarding cannabis use in children with autism spectrum disorders. Pediatrics. https://doi.org/10.1542/peds.2018-0558CrossRefPubMed

Gillespie, N. A., & Kendler, K. S. (2021). Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. JAMA Psychiatry, 78(5), 467–468.CrossRef

Goes, F. S., Pirooznia, M., Parla, J. S., Kramer, M., Ghiban, E., Mavruk, S., Chen, Y.-C., Monson, E. T., Willour, V. L., Karchin, R., Flickinger, M., Locke, A. E., Levy, S. E., Scott, L. J., Boehnke, M., Stahl, E., Moran, J. L., Hultman, C. M., Landen, M., … Potash, J. B. (2016). Exome sequencing of familial bipolar disorder. JAMA Psychiatry, 73(6), 590–597.CrossRef

Horder, J., Petrinovic, M. M., Mendez, M. A., Bruns, A., Takumi, T., Spooren, W., Barker, G. J., Kunnecke, B., & Murphy, D. G. (2018). Glutamate and GABA in autism spectrum disorder—A translational magnetic resonance spectroscopy study in man and rodent models. Translational Psychiatry, 8(1), 106.CrossRef

Huestis, M. A., Solimini, R., Pichini, R., Carlier, J., & Busardo, F. P. (2019). Cannabidiol adverse effects and toxicity. Current Neuropharmacology, 17, 974–989.CrossRef

Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162(1–3), 153–161.CrossRef

Jones, H. J., Gage, S. H., Heron, J., Hickman, M., Lewis, G., Munafò, M. R., & Zammit, S. (2018). Association of combined patterns of tobacco and cannabis use in adolescence with psychotic experiences. JAMA Psychiatry, 75(3), 240–246.CrossRef

Kuester, G., Vergara, K., Ahumada, A., & Gazmuri, A. M. (2017). Oral cannabis extracts as a promising treatment for the core symptoms of autism spectrum disorder: Preliminary experience in chilean patients. Journal of the Neurological Sciences, 381, 932–933.CrossRef

Kurz, R., & Blaas, K. (2010). Use of dronabinol (delta-9-THC) in autism: A prospective single-case study with an early infantile autistic child. Cannabinoids, 5, 4–6.

Lee, Y., Zhang, Y., Kim, S., & Han, K. (2018). Excitatory and inhibitory synaptic dysfunction in mania: An emerging hypothesis from animal model studies. Experimental & Molecular Medicine, 50(4), 12.

Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015). The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience, 16(12), 705–718.CrossRef

Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 9, 1365. https://doi.org/10.3389/fphar.2018.01365CrossRefPubMedPubMedCentral

Minshawi, N. F., Hurwitz, S., Morriss, D., & McDougle, C. J. (2015). Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: Integration of psychological and biological theory and approach. Journal of Autism and Developmental Disorders, 45(6), 1541–1568.CrossRef

Mostafavi, M., & Gaitanis, J. (2020). Autism spectrum disorder and medical cannabis: Review and clinical experience. Seminars in Pediatric Neurology, 35, 100833.CrossRef

Poleg, S., Golubchik, P., Offen, D., & Weizman, A. (2019). Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 89, 90–96.CrossRef

Politte, L. C., & McDougle, C. J. (2014). Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 231, 1023–1036.CrossRef

Pretzsch, C. M., Freyberg, J., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Edden, R. A. E., Williams, S., Murphy, D. G. M., Daly, E., & McAlonan, G. M. (2019). Effects of cannabidiol on brain excitation and inhibition systems: A randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology, 44(8), 1398–1405.CrossRef

Rabin, R. A., & George, T. P. (2017). Understanding the link between cannabinoids and psychosis. Clinical Pharmacology & Therapeutics, 101(2), 197–199.CrossRef

Rong, C., Carmona, N. E., Lee, Y. L., Ragguett, R.-M., Pan, Z., Rosenblat, J. D., Subramaniapillai, M., Shekotikhina, M., Almatham, F., Alageel, A., Mansur, R., Ho, R. C., & McIntyire, R. S. (2018). Drug-drug interactions as a result of co-administering THC and CBD with other psychotropic agents. Expert Opinion on Drug Safety, 17(1), 51–54.CrossRef

Rubenstein, J. L. R., & Merzenich, M. M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes, Brain and Behavior, 2(5), 255–267.CrossRef

Rubino, T., Guidali, C., Vigano, D., Realini, N., Valenti, M., Massi, P., & Parolaro, D. (2008). CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology, 54(1), 151–160.CrossRef

Schleider, L. B. L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019). Real life experience of medical cannabis treatment in autism: Analysis of safety and efficacy. Scientific Reports, 9(1), 200.CrossRef

Thiele, E. A., March, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., Sommerville, K., & GWPCARE4 Study Group. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 391, 1085–1096.CrossRef

Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219–2227.CrossRef

Wang, G. S. (2017). Pediatric concerns due to expanded cannabis use: Unintended consequences of legalization. Journal of Medical Toxicology, 13, 99–105.CrossRef

Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. International Journal of Molecular Sciences, 18(9), 1916.CrossRef

Titel: Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder
Auteurs: Majd Al-Soleiti
Kayla Balaj
Robyn P. Thom
Christopher J. McDougle
Christopher J. Keary
Publicatiedatum: 09-09-2021
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 9/2022
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-021-05254-8

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 9/2022

Self-Determination in Autistic Transition-Aged Youth without Intellectual Disability

An overestimation of the prevalence of ASD among psychiatric patients

Figure Disembedding: The Gottschaldt’s Hidden Figure Test in Children with Typical Development and Autism

Adults With Autism Should be Considered a Priority in COVID-19 Immunization Programs

Prevalence of Autism Spectrum Disorders in Adult Outpatient Psychiatry

Parent Perspectives on Supports and Barriers for Autistic Youth Transitioning to Adulthood